1. Home
  2. RKTO vs LGVN Comparison

RKTO vs LGVN Comparison

Compare RKTO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket One Inc. Common Stock

RKTO

Rocket One Inc. Common Stock

N/A

Current Price

$0.69

Market Cap

18.9M

Sector

Health Care

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

N/A

Current Price

$2.59

Market Cap

21.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RKTO
LGVN
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
21.4M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
RKTO
LGVN
Price
$0.69
$2.59
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $61.25
AVG Volume (30 Days)
★ 302.0K
138.4K
Earning Date
11-11-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
29.69
★ 50.76
EPS
★ N/A
N/A
Revenue
N/A
★ $709,000.00
Revenue This Year
N/A
$46.15
Revenue Next Year
N/A
$396.46
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.62
$0.48
52 Week High
$1.19
$7.60

Technical Indicators

Market Signals
Indicator
RKTO
LGVN
Relative Strength Index (RSI) 47.55 40.54
Support Level $0.62 $0.61
Resistance Level $0.93 $7.45
Average True Range (ATR) 0.07 0.34
MACD -0.00 -0.36
Stochastic Oscillator 35.74 7.92

Price Performance

Historical Comparison
RKTO
LGVN

About RKTO Rocket One Inc. Common Stock

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: